The new bio-medicine announced its cooperation with tella Group, a Japanese listed company, and authorized two important patented technologies of immune cell preparation: "DC (dendritic cell) cancer vaccine" and "super NK (natural black cell)". Domestic biopharmaceuticals imported and authorized two patented technologies for immune cell preparation from Japan.
After the release of immune cells for clinical treatment of various cancers in the Ministry of Health and Welfare, the new biomedicine released two important patented technologies of immune cell preparation, "DC (Dendritic Cell Cancer Vaccine)" and "Super NK (Natural Black Cell)", which were authorized by tella Group, a Japanese listed company. Clinicians and cancer patients are expected to benefit from Japanese immune cell culture technology and the experience accumulated in Taiwan Province Province in recent 15 years.
Pan Junyou, chairman of New Biomedical, pointed out that the DC (Dendritic Cell) cancer vaccine launched by New Product Company was developed by the University of Tokyo. In Japan, there are 22 kinds of cancers, 1 1000, including pancreatic cancer, colorectal cancer with the largest number of new cases and lung cancer with the largest number of deaths in China.
What is a dendritic cell cancer vaccine? 」
Naokita Yamashita, an emeritus professor at the University of Tokyo, said that dendritic cells (DC) are immune cells existing in human body, mainly derived from hematopoietic stem cells in human bone marrow. Dendritic cells, like the commander of the body's defense system, have the ability to swallow and present antigens. When dendritic cells recognize foreign pathogens or cancer cells, they will start phagocytosis, decompose these cancer cells into small fragments, then present the antigen of cancer cells on the surface of dendritic cells, and train T cells to know these cancer cells, so as to achieve the goal of using immune cells (T cells) to attack cancer cells accurately and effectively.
Ichiro Yazaki, president of Tella, pointed out that dendritic cell vaccine is to obtain monocytes from patients' blood, cultivate them into dendritic cells in vitro, and then add protein fragments with the characteristics of the target cancer, the so-called cancer cell antigen, so that dendritic cells can remember the characteristics of cancer cells, and then inject them into patients to induce an immune response to cancer cells. Dendritic cell vaccine can enhance the body's immune response to cancer cells, and is often used in conjunction with existing treatment methods such as surgery, radiotherapy and chemotherapy, and targeting to help the body clear the remaining cancer cells.
Professor Lai, director of the Cancer Center of Wan Fang Hospital, pointed out that the future of immune cell therapy is foreseeable, which makes patients full of expectations. Why does "dendritic cell vaccine therapy" help "cold tumors become hot and swollen?" 」
The so-called "cold tumor" and "hot tumor" actually refer to immunogenic tumors (hot tumors) and non-immunogenic tumors (cold tumors). Cold tumor means that there are no or only a few immune cells in tumor tissue. In the past, immunotherapy was ineffective for such patients alone. Dendritic cell vaccine therapy helps to increase immune cells, activate immune checkpoint inhibitors, and reduce the chance of "death grip" between tumor cells and immune cells, that is, it can play a role in poisoning cancer cells. Checkpoint inhibitors alleviate the braking effect of tumors on immune cells, and then these immune cells can easily blow the burning flame to the basement occupied by cancer cells, thus producing therapeutic effects on "hot tumors".
Dendritic cell vaccine therapy using autoimmune cells to attack cancer cells will be applied as soon as possible in the future, and it is expected to be put into clinical use in Taiwan Province Province before the end of the year at the earliest. Professor Lai, executive director of Taiwan Province Cancer Foundation and director of hospital cancer center, pointed out that NK cells provided by immune cell therapy, like various armed forces, form a sea of people to attack cancer cells. If immunoscreening inhibitors are combined, it means that the immune cells that have been arrested and liberated can get the help of immune cells again, which can greatly enhance the effect of immunotherapy.
After the implementation of the special management measures, as long as GTP laboratories equipped with qualified culture and amplification equipment draw up treatment plans and apply for clinical application through orthodox medical institutions and specialists, they will have the opportunity to apply for the treatment of cancer patients, so that the future of immune cell therapy can be expected and patients are full of expectations.